Company Overview

Novavax, Inc. is a U.S.-based biotechnology company focused on the research, development, commercialization, and licensing of vaccines for infectious diseases. The company operates within the global biotechnology and vaccine industries, with its primary commercial focus centered on protein-based vaccine technology and adjuvant systems. Novavax’s principal revenue drivers have included sales of its COVID-19 vaccine, licensing agreements, advance purchase arrangements with governments, and strategic collaborations related to vaccine development and manufacturing.

The company is best known for its recombinant nanoparticle vaccine platform and its proprietary Matrix‑M™ adjuvant technology, which is designed to enhance immune response. Novavax has targeted both pandemic and endemic infectious diseases, including COVID-19 and influenza, and has pursued combination vaccine candidates. Founded in 1987 and headquartered in Gaithersburg, Maryland, the company historically operated as a clinical-stage biotechnology firm before transitioning into commercial vaccine distribution during the COVID-19 pandemic. Its strategic positioning has emphasized differentiated protein-based vaccines as alternatives to mRNA technologies, particularly for populations seeking traditional vaccine platforms.

Business Operations

Novavax generates revenue through vaccine product sales, licensing arrangements, royalties, government-supported development agreements, and collaboration partnerships. The company’s core operations are organized around vaccine research, clinical development, regulatory approvals, manufacturing coordination, and commercialization activities. Its principal commercial asset has been Nuvaxovid/Covovax, its recombinant protein-based COVID-19 vaccine authorized or approved in multiple international markets. Novavax has also advanced pipeline programs involving influenza vaccines and combination COVID‑19/influenza candidates.

The company maintains a global operational structure through partnerships with manufacturers, distributors, and public health organizations. Novavax has historically collaborated with entities including Serum Institute of India, Takeda Pharmaceutical, and various government agencies and international health organizations. The company relies on a combination of internal scientific capabilities and outsourced manufacturing relationships to support production scale and distribution. Its proprietary assets include the Matrix‑M™ adjuvant platform and recombinant nanoparticle vaccine technology used across multiple vaccine candidates.

Strategic Position & Investments

Novavax’s strategic direction has increasingly focused on leveraging its protein-based vaccine platform to expand beyond pandemic-related demand and establish a sustainable commercial vaccine portfolio. The company has prioritized development of combination vaccines targeting both COVID‑19 and influenza, as well as next-generation standalone influenza vaccines. Management has also emphasized cost-reduction initiatives, operational restructuring, and commercial partnerships intended to stabilize finances following reduced global COVID‑19 vaccine demand.

The company has entered strategic collaborations and licensing arrangements to broaden geographic reach and strengthen commercialization capabilities. A major development involved an expanded licensing and partnership agreement with Sanofi, which included co-commercialization elements and rights related to Novavax’s COVID‑19 vaccine and vaccine technology platform. Novavax has also continued investment in its adjuvant and recombinant protein technologies, which management identifies as core long-term assets supporting future respiratory vaccine development. Public filings and investor disclosures indicate that the company continues to evaluate opportunities in seasonal respiratory disease markets and broader infectious disease applications.

Geographic Footprint

Novavax is headquartered in Gaithersburg, Maryland, United States, and operates through a combination of direct activities and international partnerships across multiple regions. The company has maintained commercial and regulatory engagement in North America, Europe, Asia-Pacific, and parts of Latin America and the Middle East. Its COVID‑19 vaccine has received authorization, approval, or emergency-use clearance in numerous countries through national regulators and international frameworks.

International manufacturing and distribution have relied heavily on regional partners, particularly in India, Japan, and Europe. Collaborations with organizations such as Serum Institute of India expanded production capacity for global supply, including lower-income markets supported through international vaccine initiatives. Novavax’s operational influence outside the United States has historically been tied to regulatory partnerships, supply agreements with governments, and international public health procurement programs.

Leadership & Governance

Novavax was founded by David Erfle and has evolved through multiple leadership transitions as it shifted from an early-stage biotechnology company to a commercial vaccine developer. The company’s governance structure follows a standard publicly traded biotechnology model, with oversight by a board of directors and executive leadership team. Leadership strategy has focused on advancing differentiated vaccine technology platforms, improving operational efficiency, and expanding commercial partnerships to support long-term sustainability.

Key executives include:

• John C. Jacobs – President and Chief Executive Officer
• James Kelly – Chief Financial Officer
• Ruxandra Draghia-Akli, M.D., Ph.D. – Executive Vice President and Head of Research & Development
• Robert M. Walker – Chief Medical Officer
• Margaret McGlynn, R.Ph. – Chair of the Board of Directors

Company disclosures, including SEC filings, investor presentations, and earnings materials, indicate leadership has prioritized pipeline diversification, strategic licensing partnerships, and disciplined capital management following volatility in global COVID‑19 vaccine demand. Some executive roles and organizational structures have changed periodically as part of broader restructuring initiatives; where public disclosures differ by reporting period, data may vary based on the timing of filings and announcements.